{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:25:40Z","timestamp":1784262340880,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM23\/00213"],"award-info":[{"award-number":["CM23\/00213"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031531","name":"Travere Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.kint.2025.09.026","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:43:26Z","timestamp":1761810206000},"page":"211-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sodium glucose cotransporter 2 inhibition does not improve active lupus nephritis in MRLlpr\/lpr mice"],"prefix":"10.1016","volume":"109","author":[{"given":"Jordi","family":"Vilardell-Vil\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conxita","family":"Jacobs-Cach\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Martos-Guillam\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aku Enam","family":"Motto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Llorens-Cebri\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Lech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Mart\u00ednez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Esparcia-Estrela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Patricio-Li\u00e9bana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Ferrer-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Leon-Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3621-0766","authenticated-orcid":false,"given":"Maria Jos\u00e9","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2025.09.026_bib1","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/acr.22539","article-title":"Classification of systemic lupus erythematosus: systemic lupus international collaborating clinics versus American College of Rheumatology criteria: a comparative study of 2,055 patients from a real-life, international systemic lupus erythematosus cohort","volume":"67","author":"In\u00eas","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.kint.2025.09.026_bib2","doi-asserted-by":"crossref","first-page":"8981","DOI":"10.3390\/ijms25168981","article-title":"Lupus nephritis from pathogenesis to new therapies: an update","volume":"25","author":"Roveta","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2025.09.026_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41577-022-00816-y","article-title":"Glomerulonephritis: immunopathogenesis and immunotherapy","volume":"23","author":"Anders","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.kint.2025.09.026_bib4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41584-024-01158-w","article-title":"Lupus nephritis-related chronic kidney disease","volume":"20","author":"Lichtnekert","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.kint.2025.09.026_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.kint.2025.09.026_bib6","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/ndt\/gfac304","article-title":"The influence of repeated flares in response to therapy and prognosis in lupus nephritis","volume":"38","author":"Perez-Arias","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.09.026_bib7","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/ckj\/sfad055","article-title":"Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)","volume":"16","author":"Rojas-Rivera","year":"2023","journal-title":"Clin Kidney J"},{"issue":"1S","key":"10.1016\/j.kint.2025.09.026_bib8","first-page":"S1","article-title":"KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.026_bib9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.09.026_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.09.026_bib11","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3390\/jcm8060864","article-title":"The new era for reno-cardiovascular treatment in type 2 diabetes","volume":"8","author":"Garc\u00eda-Carro","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.kint.2025.09.026_bib12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.09.026_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.09.026_bib14","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13228","article-title":"Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease","volume":"5","author":"Ma","year":"2017","journal-title":"Physiol Rep"},{"key":"10.1016\/j.kint.2025.09.026_bib15","article-title":"Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2025.09.026_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112823","article-title":"Enhanced cardiorenal protective effects of combining SGLT2 inhibition, endothelin receptor antagonism and RAS blockade in type 2 diabetic mice","volume":"23","author":"Vergara","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2025.09.026_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1415879","article-title":"SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db\/db mice","volume":"15","author":"Martos-Guillami","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.kint.2025.09.026_bib18","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1681\/ASN.2019070703","article-title":"Drug testing for residual progression of diabetic kidney disease in mice beyond therapy with metformin, ramipril, and empagliflozin","volume":"31","author":"Motrapu","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.026_bib19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ndt\/gfad175","article-title":"Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis","volume":"39","author":"Caravaca-Font\u00e1n","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.09.026_bib20","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1136\/annrheumdis-2022-222512","article-title":"SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection","volume":"81","author":"Morales","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2025.09.026_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002686","article-title":"Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I\/II trial","volume":"8","author":"Wang","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.kint.2025.09.026_bib22","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/ard-2023-224242","article-title":"SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy","volume":"82","author":"Zhao","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2025.09.026_bib23","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1136\/ard-2023-225248","article-title":"Correspondence on: \u201cSGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy\u201d by Zhao et al","volume":"83","author":"Soler","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2025.09.026_bib24","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1016\/j.ekir.2025.06.036","article-title":"The protective effects of SGLT-2 inhibitors against postoperative acute kidney injury in type 2 diabetes","volume":"10","author":"Song","year":"2025","journal-title":"Kidney Int Rep"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825008488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825008488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:33:13Z","timestamp":1778941993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253825008488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0085253825008488"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2025.09.026","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium glucose cotransporter 2 inhibition does not improve active lupus nephritis in MRLlpr\/lpr mice","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.10.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.09.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}